Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A sweeping 30-year review finds that legalizing cannabis — medically or recreationally — raises cannabis use among young adults and boosts ER visits, but may actually cut opioid prescribing and tobacco use. The effects on alcohol are more nuanced: medical legalization may reduce drinking, while recreational legalization appears to increase it among young adults. Researchers say it's still early days for drawing firm conclusions.
A major systematic review from McGill University, published in The Milbank Quarterly, analyzed 176 studies across 30 years and multiple countries to assess how cannabis policy reforms affect substance use and public health. The verdict? It's complicated — but not entirely grim.
Cannabis legalization was tied to increased cannabis use among young adults and a rise in cannabis-related ER visits and poison center reports. However, most studies found no change or a decrease in opioid-related healthcare use and prescribing after legalization — a potentially significant upside. Tobacco use also appeared to decline across age groups, though Canada's robust anti-smoking campaigns likely played a role.
Alcohol told a split story: medical legalization was linked to reduced drinking (suggesting some patients swap alcohol for cannabis), while recreational legalization correlated with increased alcohol use among young adults — pointing to co-use rather than substitution.
Key Takeaways:
Why it matters: With cannabis now legal in multiple countries, understanding its ripple effects on other substance use is critical for shaping public health strategy and guiding clinical practice.
